Polycyclo ring system having the diazine ring as one of the cyclos

Subclass of:

544 - Organic compounds -- part of the class 532-570 series

544000000 - ORGANIC COMPOUNDS (CLASS 532, SUBCLASS 1)

544000000 - HETEROCYCLIC CARBON COMPOUNDS CONTAINING A HETERO RING HAVING CHALCOGEN (I.E., OXYGEN, SULFUR, SELENIUM, OR TELLURIUM) OR NITROGEN AS THE ONLY RING HETERO ATOMS (Class 540, subclass 1)

544001000 - Hetero ring is six-membered having two or more ring hetero atoms of which at least one is nitrogen (e.g., selenazines, etc.)

544224000 - The six-membered hetero ring consists of two nitrogens and four carbons (e.g., 1,2-diazines, etc.)

544242000 - 1,3-diazines

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application number	Description	Number of patent applications / Date published
544253000	Bicyclo ring system having the diazine ring as one of the cyclos	243
544249000	Tricyclo ring system having the diazine ring as one of the cyclos	33
544246000	Tetracyclo ring system having the diazine ring as one of the cyclos	7

Entries
Document	Title	Date
20080255357	Terrylene and Quaterrylene Derivatives - Rylene derivatives of the general formula I	10-16-2008
20080269485	FLUORINATED DYES AND THEIR USE IN ELECTROPHORETIC DISPLAY DEVICES - This invention relates to process for preparing fluorinated dyes selected from the group consisting of compounds of the general formulae (I) and (III) and mixtures thereof by reacting the corresponding compounds which do not have R	10-30-2008
20080300405	Naphthalenetetracarboxylic Aicd Derivatives and their Use as Semiconductors - The present invention relates to naphthalenetetracarboxylic acid derivates, to a process for their preparation and to their use, especially as an n-type semiconductor.	12-04-2008
20110275807	Application of Evodiamine in preparing medicaments for Alzheimer's disease - A method of preparing medicaments for Alzheimer's disease includes the step of administering Evodiamine. Evodiamine can improve the main symptom of Alzheimer's disease, namely, the loss of learning and memory abilities, and delay the progress of Alzheimer's disease. The effects of Evodiamine are represented by following two aspects. Firstly, it can inhibit the over-activation of the microglias in the brain tissue, consistent with the reduction of the over-expression of the cytokines IL-Iβ, IL-6 and TNF-α. Secondly, it can reduce the expression of the cyclaoxygenase-2 thus inhibiting the inflammation in the central nervous system. Researches on curative effects and molecular mechanism of applying Evodiamine to Alzheimer's disease have proved that Evodiamine has a good therapeutic effect and has a potential to develop into a clinical therapy medicament.	11-10-2011
20130123495	HALOGEN-CONTAINING PERYLENETETRACARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF - The invention relates to compounds of the formula (I)	05-16-2013
20140005390	TETRAAZAPEROPYRENE COMPOUNDS AND THEIR USE AS N-TYPE SEMICONDUCTORS	01-02-2014
20140155603	HALOGEN-CONTAINING PERYLENETETRACARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF - The invention relates to compounds of the formula (I)	06-05-2014